Dr Reddys Laboratories (RDY) EBIT (2012 - 2026)

Dr Reddys Laboratories' EBIT history runs 15 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• In Q1 2026, EBIT fell 92.89% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $582.4 million (down 31.48% YoY), while the FY2026 annual figure was $539.0 million, down 35.99% from the prior year.
• EBIT was $14.5 million for Q1 2026 at Dr Reddys Laboratories, down from $159.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $221.7 million in Q4 2024 to a low of $14.5 million in Q1 2026.
• Historically, EBIT has averaged $184.8 million across 5 years, with a median of $204.0 million in 2025.
• The sharpest annual moves came in 2022 and 2026: EBIT surged 693.62% in 2022, then slumped 92.89% in 2026.
• A 5-year view of EBIT shows it stood at $150.8 million in 2022, then soared by 37.53% to $207.4 million in 2023, then climbed by 6.91% to $221.7 million in 2024, then declined by 27.89% to $159.9 million in 2025, then slumped by 90.93% to $14.5 million in 2026.
• The last three EBIT figures came in at $14.5 million (Q1 2026), $159.9 million (Q4 2025), and $204.2 million (Q2 2025), per Business Quant data.